News

The ALS Association has announced its new Translational Research Advancing Therapy for ALS (TREAT ALS) Drug Development Contract grant program, which will fund research for the development of new treatments for amyotrophic lateral sclerosis (ALS). According to a press release, the program will support research from early target identification…

Simplesa, a nutrition company established in 2013 after the amyotrophic lateral sclerosis (ALS) community showed its support for its metabolic supplement called the Deanna Protocol, or DP diet, has expanded the Deanna Protocol Bundle Pack choices for consumers. The Deanna Protocol is an all-natural metabolic program developed by Dr. Vincent Tedone, a…

U.S. veterans who fought in the Persian Gulf War of 1990-91 appear to be at an increased risk for amyotrophic lateral sclerosis (ALS), according to report from the Institute of Medicine (IOM) of the National Academies of Sciences, Engineering, and Medicine. The U.S. Department of Veterans Affairs had requested the review, evaluating and summarizing…

Belgian researchers found the downstream effects of a mutation in the gene C9orf72, identified in 2011 as one of the main genetic factors behind amyotrophic lateral sclerosis (ALS). This specific mutation interferes with nuclear transport of proteins in and out of the cell nucleus and contributes to ALS development. About 10 percent of…

Researchers discovered that a metalloproteinase specialized in the degradation of chondroitin sulfate proteoglycans, called ADAMTS-4, promotes neurodegeneration in a mouse model for human amyotrophic lateral sclerosis (ALS). The study, “ADAMTS-4 promotes neurodegeneration in a mouse model of amyotrophic lateral sclerosis,” was published in the journal Molecular Neurodegeneration. ALS,…

Baylor College of Medicine and the Belgium-based biopharmaceutical company UCB announced that they have entered into a strategic partnership, led by Baylor Professor Huda Zoghbi, to discover new medicines to better treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The research alliance is in keeping UCB’s commitment to accelerating the discovery…

The Target ALS Foundation, a collaborative research consortium, received a $5 million matching-gift donation from Biogen to help establish the foundation’s new Industry Fund for ALS Research, supporting a network of private-public research laboratories working to develop effective treatments and, ideally, a cure for amyotrophic lateral sclerosis (ALS). “Biogen is deeply committed to ALS…

The ALS Association (ALSA) recently held its sixth annual Heroes Luncheon, honoring outstanding people with amyotrophic lateral sclerosis (ALS) whose efforts have made significant contributions to the ALS community. The four honorees at the Feb. 5 luncheon in Atlanta, Georgia, were: Nanci Ryder, a Hollywood publicist and co-founder of…

The ALS Association announced that it has awarded a total of $755,855 in financial grants supporting new clinical management projects to address unmet needs in amyotrophic lateral sclerosis (ALS) care. For this grant program, the ALS Association defined areas of priority research and invited experts to submit their proposals, according to a…

ProMIS Neurosciences announced that it has established Business (BAB) and Scientific (SAB) advisory boards to advance the company’s work. ProMIS is developing its first products focused on more effective treatments of amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD). “Our number one goal is to create the appropriate precision therapeutics and companion diagnostics…